CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 19 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Placebo 0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00828061
NCT00828061Phase 1Completed
CompareCT.gov

A Randomized Clinical Trial to Study the Effects of Single Dose of Corticosteroid on Response to Nasal Allergen Challenge in Patients

Merck Sharp & Dohme LLC·interventional·Posted Jan 23, 2009·Updated Apr 2, 2019

In Brief

A Phase 1 clinical trial evaluating Placebo and prednisone for Allergic Rhinitis. Completed, enrolled 19 participants.

Detailed Summary

This study will investigate whether changes in inflammatory mediators produced by the nose after exposure to an allergen can be used to evaluate the anti-inflammatory effects of novel drugs for the treatment of allergic asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 23, 2009
Enrollment StartFeb 4, 2009
Primary CompletionMay 7, 2009
Study CompletionMay 21, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.4 years ago

Interventions

Placebodrug

Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks

prednisonedrug

Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.

prednisonedrug

Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.